IMV Inc. initiated with a Buy at H.C. Wainwright. H.C. Wainwright analyst Joseph Pantginis started IMV Inc. with a Buy rating and $11.50 price target. The analyst has a favorable view of the company’s proprietary DPX platform technology, which he says is a cancer vaccine-like therapeutic approach with key differences.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.